Alcobra Ltd. (NASDAQ:ADHD) will be issuing its Q316 quarterly earnings data on Tuesday, November 15th. Analysts expect the company to announce earnings of ($0.26) per share for the quarter.

Alcobra (NASDAQ:ADHD) last announced its quarterly earnings results on Tuesday, August 30th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.01. On average, analysts expect Alcobra to post $-0.93 EPS for the current fiscal year and $-0.96 EPS for the next fiscal year.

Earnings History for Alcobra (NASDAQ:ADHD)

Alcobra Ltd. (NASDAQ:ADHD) opened at 1.94 on Monday. The firm has a 50-day moving average price of $2.52 and a 200 day moving average price of $4.09. The company’s market cap is $53.47 million. Alcobra Ltd. has a one year low of $1.77 and a one year high of $6.80.

A number of hedge funds have recently bought and sold shares of the stock. KCG Holdings Inc. purchased a new stake in Alcobra during the third quarter valued at $117,000. VHCP Management LLC boosted its stake in Alcobra by 28.7% in the second quarter. VHCP Management LLC now owns 623,313 shares of the company’s stock valued at $2,799,000 after buying an additional 138,813 shares during the last quarter. VHCP Management II LLC boosted its stake in Alcobra by 28.7% in the second quarter. VHCP Management II LLC now owns 1,454,402 shares of the company’s stock valued at $6,530,000 after buying an additional 323,902 shares during the last quarter. Jefferies Group LLC purchased a new stake in Alcobra during the second quarter valued at $533,000. Finally, BlackRock Fund Advisors boosted its stake in Alcobra by 1.8% in the second quarter. BlackRock Fund Advisors now owns 361,130 shares of the company’s stock valued at $1,621,000 after buying an additional 6,516 shares during the last quarter. 73.62% of the stock is currently owned by institutional investors and hedge funds.

Several research analysts have recently commented on the company. Roth Capital set a $8.00 price objective on Alcobra and gave the stock a “buy” rating in a report on Saturday, October 1st. Zacks Investment Research downgraded Alcobra from a “hold” rating to a “sell” rating in a report on Monday, July 18th. WBB Securities upgraded Alcobra from a “sell” rating to a “hold” rating and reduced their price target for the company from $4.00 to $1.90 in a report on Wednesday, November 2nd. Barclays PLC initiated coverage on Alcobra in a report on Monday, August 1st. They set an “equal weight” rating and a $8.00 price target on the stock. Finally, Piper Jaffray Cos. downgraded Alcobra from an “overweight” rating to a “neutral” rating and reduced their price target for the company from $10.00 to $3.00 in a report on Thursday, September 29th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and five have given a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $5.14.

About Alcobra

Alcobra Ltd is an Israel-based Biopharmaceutical company. It focuses on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder (ADHD), a common and morbid neuropsychiatric condition in children and adults. Adult ADHD is associated with increased health risks and healthcare costs, higher divorce rates, lower levels of socioeconomic attainment, lower academic achievement, unemployment and work place deficits, increased risks for motor vehicle accidents, greater likelihood of additional psychiatric disorders, increased criminal activity and incarceration, and higher rates of substance use and abuse.

5 Day Chart for NASDAQ:ADHD

Receive News & Stock Ratings for Alcobra Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alcobra Ltd. and related stocks with our FREE daily email newsletter.